Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

This Phase Ib trial evaluated ficlatuzumab, a first-in-class anti-HGF antibody, in combination with cytarabine in acute myeloid leukemia (AML) patients. Among 17 evaluable patients, the overall response rate was 53%, all complete remissions.